Business Context and Reporting Period
Company: Rein Therapeutics, Inc. (RNTX)
Filing Type: Form 8-K (Current Report)
Date of Report: April 21, 2025
Reporting Period: Event date April 21, 2025; Expected closing on or about April 24, 2025.
The Company entered into privately negotiated agreements to facilitate the exercise and exchange of outstanding warrants issued in 2023 and 2024, alongside a private placement of pre-funded warrants.
Key Financial Metrics and Transaction Details
| Metric | Value/Detail |
|---|---|
| Expected Gross Proceeds | Approximately $5.05 million |
| Warrant Exercises (Cash) | 159,500 shares (2023 Warrants) + 743,429 shares (2024 Warrants) |
| Reduced Exercise Price | $1.60 per share |
| Warrant Exchanges | 1,939,000 shares (2023 Warrants surrendered for Pre-Funded Warrants) |
| Private Placement | 312,695 shares (Placement Pre-Funded Warrants) |
| Pre-Funded Warrant Price | $1.599 per share (underlying share price $0.001) |
| Key Counterparty | Entities affiliated with Bios Equity Partners, LP |
Note: This filing does not provide revenue, profit, cash flow, or margin data as it reports a specific capital transaction rather than periodic financial results.
Material Changes and Transaction Structure
- Warrant Inducement: Holders of 2023 and 2024 warrants agreed to exercise for cash at a reduced price of $1.60 per share, down from original terms, with deadlines of April 24, 2025, and May 1, 2025, respectively.
- Warrant Exchange: Holders surrendered 1,939,000 shares of 2023 Warrants in exchange for Pre-Funded Warrants. This included a cash payment of $1.599 per share by the holders.
- Private Placement: An entity affiliated with Bios Partners agreed to purchase an additional 312,695 Pre-Funded Warrants at $1.599 per share.
- Registration Rights: The Company agreed to file a resale registration statement within 90 days if the Bios Purchaser and affiliates beneficially own more than 9.99% of outstanding common stock.
Outlook, Risks, and Contingencies
- Closing Contingency: The Transactions are expected to close on or about April 24, 2025, subject to satisfaction of closing conditions. There is no assurance the transactions will be completed on anticipated terms or at all.
- Beneficial Ownership Limits: Pre-Funded Warrants are subject to beneficial ownership limitations (default 4.99% or 9.99%, adjustable up to 19.99% with 61-day notice).
- Legal and Regulatory: The offering relies on Section 4(a)(2) of the Securities Act of 1933 as an exemption from registration. The securities are not registered and may not be sold absent registration or an applicable exemption.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the Transactions. Actual results may differ materially due to risks and uncertainties.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $5.05 million gross proceeds receipt.
- Confirm the final number of shares issued upon exercise of the 2023 and 2024 warrants.
- Monitor the filing of the resale registration statement if Bios Partners' ownership exceeds 9.99%.
- Review the Company's most recent Form 10-K for updated risk factors and liquidity status, as this 8-K does not contain comprehensive financial statements.
- Check for any subsequent filings regarding the satisfaction of closing conditions for the Private Placement.